



Lung Cancer Europe

Funding sources

LUNG CANCER EUROPE (LUCE)

2023

LUCE Industry related income				
Name of company / funder	Amount of income	Currency	% of overall organisation's income	
AMGEN	49'810.00	CHF	6.51%	
ASTRAZENECA	39'908.00	CHF	5.21%	
BLUEPRINT	21'722.13	CHF	2.83%	
BOEHRINGER INGELHEIM	34'569.50	CHF	4.51%	
BRISTOL-MYERS	59'862.00	CHF	7.82%	
ELI LILLY	34'349.00	CHF	4.49%	
HOFFMANN-LA ROCHE	59'262.00	CHF	7.75%	
MSD INTERNATIONAL	49'385.00	CHF	6.46%	
NOVARTIS	29'631.00	CHF	3.87%	
GILEAD SCIENCES IRELAND	29'118.00	CHF	3.81%	
TAKEDA	45'144.00	CHF	5.90%	
BAYER	19'954.00	CHF	2.61%	
REGENERON PHARMACEUTICALS INC	66'405.10	CHF	8.68%	
DAIICHI SANKYO	44'446.50	CHF	5.81%	
MERCK HEALTHCARE	38'473.50	CHF	5.03%	
LIFE TECHNOLOGIES	30'096.00	CHF	3.94%	
JANSSEN	30'042.00	CHF	3.93%	
NOVOCURE	27'655.60	CHF	3.62%	
OTHER REFUNDS INDUSTRY			0.00%	
Subtotal	709'833.33	CHF	92.78%	

LUCE Non-industry income - public funding			
Name of company / funder	Amount of income	Currency	% of overall organisation's income
OTHER REFUNDS NON-INDUSTRY	2'028.40	CHF	0.27%
Subtotal	2'028.40	CHF	0.27%

LUCE Non-industry related income			
Name of company / funder	Amount of income	Currency	% of overall organisation's income
MEMBER CONTRIBUTION	2'685.10	CHF	0.35%
ESO	-	CHF	0.00%
OTHER REFUNDS NON-INDUSTRY	50'394.75	CHF	6.60%
Subtotal	53'079.85	CHF	6.95%

TOTAL	764'941.58	CHF	100.00%
--------------	-------------------	------------	----------------

Information required to be included on organisation's website

Funding sources	@ URL LUCE
Overall proportion of industry and non-industry	Industry: 92.78%; Non-industry: 7.22%
Percentage of the highest contribution from a single company	8.68% of overall organisations income